Tharimmune, Inc. (NASDAQ:THAR) Sees Large Growth in Short Interest

Tharimmune, Inc. (NASDAQ:THAR) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 63,500 shares, a growth of 17.2% from the January 15th total of 54,200 shares. Based on an average trading volume of 261,400 shares, the short-interest ratio is currently 0.2 days. Approximately 4.4% of the company’s shares are sold short.

Tharimmune Stock Performance

NASDAQ:THAR opened at $1.90 on Friday. The firm has a fifty day simple moving average of $2.06 and a two-hundred day simple moving average of $2.40. Tharimmune has a 12 month low of $1.84 and a 12 month high of $7.46.

Institutional Investors Weigh In On Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. Virtu Financial LLC purchased a new position in Tharimmune, Inc. (NASDAQ:THAR) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 21,371 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned 1.11% of Tharimmune at the end of the most recent quarter. 1.16% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on THAR. RODMAN&RENSHAW raised shares of Tharimmune to a “strong-buy” rating in a research note on Friday, December 6th. Rodman & Renshaw began coverage on shares of Tharimmune in a research note on Friday, December 6th. They set a “buy” rating and a $17.00 target price for the company.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).